Seawolf Therapeutics raised $100 million
Seawolf Therapeutics received $100 million to support its research into DNA-based therapies. The deal includes partners like Versant Ventures, Eli Lilly, CRISPR Therapeutics, and Sanofi, which could pay up to $1.2 billion in milestone payments.
- Field
- gene therapy
- What they did
- Seawolf Therapeutics received $100 million to develop DNA-based therapies, including a partnership with Sanofi.
- Why it matters
- According to the agreement, the company could receive up to $1.2 billion for meeting milestones and receiving royalties from future products.
#dna therapeutics#seawolf therapeutics#versant ventures#sanofi#seed funding



